Pharmafocus spoke to Scott Curley, general manager of Amarin UK and Ireland, about the lessons the COVID-19 pandemic taught the pharma industry in regards to the ongoing battles with CVD
Rhian Linney, associate communications director at Galapagos UK and Ireland, tells Pharmafocus about the significance of the patient voice in autoimmune conditions, focusing on rheumatoid arthritis
Nikunj Desai, head of supply chain at ACG, explores how supply chains can be made more secure and the impacts this may have on the pharma industry
Page 5 – NHS to offer artificial pancreas to type 1 diabetes patients
Page 6 – AstraZeneca moves manufacturing to Ireland due to Britain’s tax regime
Page 7 – Australia’s TGA approves psychedelics to treat mental health conditions
Page 9 – Johnson & Johnson’s Ethicon undertakes first robot-assisted kidney stone removal
Page 12 – AI finds liver cancer drug candidate in only 30 days
Executive Director – PMGroup Worldwide Ltd
Karl Equi
Group Managing Editor
Iona Everson
Editorial Assistants
Betsy Goodfellow
betsy@pharmafile.com
James Spargo
james@samedanltd.com
Sales Manager
Eliot Haynes
Design & Layout
Peter May
Pharmafocus is published by:
Samedan Ltd
Suite E, 11 Bell Yard Mews,
175 Bermondsey Street,
London, SE1 3TN
Tel: +44 (0)20 7724 3456
Fax: +44 (0)20 7403 7747
Subscriptions & Data Management
Curwood CMS Tel: 01580 883840
ISSN: 1465-5403
Pharmafocus is sent free of charge to selected permanent employees of ethical and OTC pharmaceutical and biotech companies. Employees are specifiers from middle and senior management with responsibility for making buying decisions. Selection is at the discretion of the Publisher. Copies are also available on a subscription basis at an annual fee of £115 (UK), £145 (Europe) and £185 (RoW).
All subscriptions payable to Samedan. Back copies can be purchased for £15.00 each. Pharmafocus is published by Samedan Ltd. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form without permission, unless for the purposes of reference and comment.
©2022 Samedan Ltd, Pharmaceutical Publishers
The opinions and views expressed by contributors to this publication are not necessarily those of the Editor or the Publisher and, while every care has been taken in the preparation of the newspaper, the Editor and the Publisher are not responsible for such opinions and views, or for any inaccuracies in the articles. The Publisher is not responsible for any images supplied by contributors. While every care is taken with artwork supplied, the Publisher cannot be held responsible for any loss or damage incurred. The entire content of this publication is protected by copyright. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, by any means – electronic, mechanical, photocopying or otherwise – without the prior permission of the Publisher.